Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Bio-Rad Laboratories, Inc. (NYSE: BIO).

Full DD Report for BIO

You must become a subscriber to view this report.


Recent News from (NYSE: BIO)

Bio-Rad Quality Controls Now Available for Multiple Abbott Clinical Diagnostics Platforms
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced expanded global access of the company’s quality controls across multiple Abbott clinical diagnostics platforms that now includes the Abbott Alini...
Source: Business Wire
Date: December, 03 2018 08:30
New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omeros Corporation (NASDAQ:OMER), Apple Inc. (NASDAQ:AAPL), Bio-Rad La...
Source: GlobeNewswire
Date: November, 30 2018 08:25
Bio-Rad and the University of Chicago Win Patent Infringement Case Against 10X Genomics Related to Droplet Microfluidics Technologies
A Federal District Court jury yesterday found that 10X Genomics willfully infringed three United States patents owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products (NYSE: BIO and...
Source: Business Wire
Date: November, 14 2018 08:30
Biome Grow subsidiary, Highland Grow, receives license to sell to other licensed producers from Health Canada
TORONTO, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“ Biome ” or the “ Company ”) (CSE:BIO) (Frankfurt:6OTA ) is pleased to announce its Nova Scotia-based subsidiary, Highland Grow Inc. (“ Highland Grow ”), has received its license to sell to ...
Source: Thomson Reuters ONE
Date: November, 14 2018 08:00
Bio-Rad Wins USDA Contract for Its Pathogen Detection Testing Products
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company has been awarded a contract for iQ-Check real-time PCR pathogen detection test kits and the iQ-Check Prep Automation System from the Un...
Source: Business Wire
Date: November, 13 2018 08:30
GBT Reports Third Quarter And 9M18 Results
MONTEVIDEO, Uruguay, Nov. 12, 2018 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America , announced today its results for the 3Q18 and 9M18. HIGHLIGHTS Net revenues for 3Q18 increased by 2% in constant currenc...
Source: PR Newswire
Date: November, 12 2018 22:07
Biome Grow Provides Further Information on Supply and Production Agreement with Province of Newfoundland and Labrador
TORONTO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“ Biome ” or the “ Company ”) (CSE:BIO) (Frankfurt:6OTA ) announced Friday November 2, 2018 that its Newfoundland and Labrador brand, Back Home Cannabis Corporation (“ Back Home ”) has entere...
Source: Thomson Reuters ONE
Date: November, 05 2018 06:00
Biome Grow announces supply and production agreement with Province of Newfoundland and Labrador, including distribution and retail services
Agreement is the largest supply agreement in Atlantic Canada TORONTO, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“ Biome ” or the “ Company ”) (CSE:BIO) (Frankfurt:6OTA) proudly announces that its Newfoundland and Labrador brand, Back Home Medical Canna...
Source: Thomson Reuters ONE
Date: November, 02 2018 08:30
Bio-Rad Laboratories (BIO) Q3 2018 Results - Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q3 2018 Earnings Call November 01, 2018 5:00 pm ET Executives Ronald W. Hutton - Bio-Rad Laboratories, Inc. Christine A. Tsingos - Bio-Rad Laboratories, Inc. John Hertia - Bio-Rad Laboratories, Inc. Norman D. Schwartz - Bio-Rad Laboratories, Inc...
Source: SeekingAlpha
Date: November, 01 2018 22:05
Bio-Rad Labs misses by $0.24, beats on revenue
Bio-Rad Labs (NYSE: BIO ): Q3 Non-GAAP EPS of $0.91 misses by $0.24 ; GAAP EPS of $8.89. Revenue of $545.1M (+2.1% Y/Y) beats by $3.87M . Press Release More news on: Bio-Rad Laboratories, Inc., Earnings news and commentary, Tech stocks news,
Source: SeekingAlpha
Date: November, 01 2018 16:39

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-08315.56313.74317.175313.0296,336
2018-05-17291.26286.82291.26284.20391,342
2017-11-07260.99262.22263.77257.59302,396
2017-11-06261.42259.82265.88258.5479348,043
2017-11-03241.11261.42262.49236.34746,393

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-104451,48629.9462Cover
2018-12-078051,62849.4472Short
2018-12-061,3592,19162.0265Short
2018-12-041,6525,73828.7905Cover
2018-12-031,2212,51048.6454Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BIO.


About Bio-Rad Laboratories, Inc. (NYSE: BIO)

Logo for Bio-Rad Laboratories, Inc. (NYSE: BIO)

Not available

 

Contact Information

 

 

Current Management

  • David Schwartz / President, CEO
  • James J. Bennett / COO
  • Thomas L. Braje / CFO
  • Sanford S. Wadler / Secretary

Current Share Structure

  • Market Cap: $7,039,406,967 - 05/11/2018
  • Issue and Outstanding: 24,701,407 - 04/10/2018

 


Recent Filings from (NYSE: BIO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 04 2018
Specialized Disclosure Report
Filing Type: SDFiling Source: edgar
Filing Date: May, 04 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 02 2018

 

 


Daily Technical Chart for (NYSE: BIO)

Daily Technical Chart for (NYSE: BIO)


Stay tuned for daily updates and more on (NYSE: BIO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: BIO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BIO and does not buy, sell, or trade any shares of BIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/